Status:
TERMINATED
CASTRO1 - Study on CRP Apheresis After Ischemic Stroke
Lead Sponsor:
Pentracor GmbH
Conditions:
Stroke, Ischemic
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
CASTRO1 is a study to investigate the reduction of C-reactive protein (CRP) by therapeutic apheresis (CRP-apheresis) in patients after primary treatment of ischemic stroke. The term therapeutic apher...
Detailed Description
The purpose of the study is to evaluate the safety and efficacy of CRP apheresis in patients following ischemic stroke. CRP apheresis is to be conducted with the aim of reducing cerebral damage follow...
Eligibility Criteria
Inclusion
- Ischaemic stroke with determination of infarct size by imaging (MRI)
- NIHSS 1-24
- CRP increase ≥ 5 mg/l within presumed 72 hours after stroke and/or CRP value \> 10 mg/l
- written informed consent of the patient or his legal representative
Exclusion
- age \< 18 years
- Severe dysphagia (danger of aspiration pneumonia)
- Clinical or laboratory evidence of a severe systemic infection
- Participation in other interventional studies
- Contraindications against apheresis therapy
- Modified Rankin Scale (mRS) before index event ≥ 3
- Intracranial hemorrhage
- Epileptic seizure in the context of the acute event
- Pregnancy, lactation
Key Trial Info
Start Date :
January 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT04417231
Start Date
January 28 2021
End Date
December 31 2022
Last Update
May 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abteilung für Neurologie, Universität Ulm
Ulm, Bavaria, Germany